Eisai-Site Updates
https://www.eisai.com/index.html
English News Release,Information,Latest News.EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL
https://www.eisai.com/news/2024/news202422.html
Eisai's news release EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL is posted. 2024-03-29T08:30:00+09:00EISAI’S BRAIN HEALTH SELF-CHECK TOOL “NOUKNOW®” IS CERTIFIED AS “ME-BYO BRAND” BY KANAGAWA PREFECTURE
https://www.eisai.com/news/2024/news202420.html
Eisai's news release EISAI’S BRAIN HEALTH SELF-CHECK TOOL “NOUKNOW®” IS CERTIFIED AS “ME-BYO BRAND” BY KANAGAWA PREFECTURE is posted. 2024-03-28T15:00:00+09:00DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024
https://www.eisai.com/news/2024/news202419.html
Eisai's news release DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024 is posted. 2024-03-28T14:00:00+09:00Sustainability "Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets ー Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships"
https://www.eisai.com/sustainability/atm/ntds/activity/049.html
Eisai's latest news Sustainability "Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets ー Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships" is posted. 2024-03-27T13:48:36+09:00Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
https://www.eisai.com/news/2024/news202418.html
Eisai's news release Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S. is posted. 2024-03-25T08:35:00+09:00DELIBERATIONS AT THE CHMP REGARDING THE MARKETING AUTHORIZATION APPLICATION IN THE EU FOR LECANEMAB HAVE BEEN RESCHEDULED DUE TO PROCEDURAL REASONS AT THE EUROPEAN MEDICINES AGENCY
https://www.eisai.com/news/2024/news202417.html
Eisai's news release DELIBERATIONS AT THE CHMP REGARDING THE MARKETING AUTHORIZATION APPLICATION IN THE EU FOR LECANEMAB HAVE BEEN RESCHEDULED DUE TO PROCEDURAL REASONS AT THE EUROPEAN MEDICINES AGENCY is posted. 2024-03-22T20:30:00+09:00Lifenet and Eisai Co-Develop Dementia Insurance “be”
https://www.eisai.com/news/2024/news202416.html
Eisai's news release Lifenet and Eisai Co-Develop Dementia Insurance “be” is posted. 2024-03-21T15:00:00+09:00EISAI SELECTED AS A NADESHIKO BRAND 2024 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
https://www.eisai.com/news/2024/news202415.html
Eisai's news release EISAI SELECTED AS A NADESHIKO BRAND 2024 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE is posted. 2024-03-21T15:00:00+09:00IR “Information Meeting 2024 [Material, Webcast]”
https://www.eisai.com/ir/library/presentations/index.html
Eisai's latest news IR “Information Meeting 2024 [Material, Webcast]” is posted. 2024-03-11T16:00:00+09:00IR “Presentation Material for Press Conference 2024”
https://www.eisai.com/ir/library/presentations/index.html
Eisai's latest news IR “Presentation Material for Press Conference 2024” is posted. 2024-03-07T14:30:00+09:00EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE TO BETTER SERVE PATIENTS
https://www.eisai.com/news/2024/news202414.html
Eisai's news release EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE TO BETTER SERVE PATIENTS is posted. 2024-03-06T08:30:00+09:00EISAI TO PRESENT DATA ON LECANEMAB AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING
https://www.eisai.com/news/2024/news202413.html
Eisai's news release EISAI TO PRESENT DATA ON LECANEMAB AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING is posted. 2024-02-29T08:30:00+09:00EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION,AIMING TO ACHIEVE NET ZERO BY 2050
https://www.eisai.com/news/2024/news202412.html
Eisai's news release EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION,AIMING TO ACHIEVE NET ZERO BY 2050 is posted. 2024-02-21T08:30:00+09:00EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2023” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY”, RECOGNIZED AS COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
https://www.eisai.com/news/2024/news202411.html
Eisai's news release EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2023” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY”, RECOGNIZED AS COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES is posted. 2024-02-20T08:30:00+09:00METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN
https://www.eisai.com/news/2024/news202410.html
Eisai's news release METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN is posted. 2024-02-15T15:30:00+09:00